CELG-RI — BRISTOL MYERS SQUIBB CO
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 14272 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 11,892,000,000 | 8,935,000,000 | -5,638,000,000 | 1,211,000,000 | 92,603,000,000 | 10,346,000,000 | 76,215,000,000 |
| Dec 2023 | 10,966,000,000 | 8,460,000,000 | -4,614,000,000 | 1,928,000,000 | 95,159,000,000 | 11,464,000,000 | 65,674,000,000 |
| Dec 2022 | 11,218,000,000 | 8,865,000,000 | -4,492,000,000 | 1,606,000,000 | 96,820,000,000 | 9,123,000,000 | 65,702,000,000 |
| Dec 2021 | 11,624,000,000 | 9,333,000,000 | -4,902,000,000 | 1,546,000,000 | 109,314,000,000 | 13,979,000,000 | 73,308,000,000 |
Annual Trend (SEC EDGAR, last 10y)
Revenues vs Net Income (last 10y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 45,006,000,000 | -29,857,000,000 | 8,025,000,000 | 92,603,000,000 | 76,215,000,000 | — | — |
| Dec 2023 | 46,159,000,000 | -30,659,000,000 | 6,327,000,000 | 95,159,000,000 | 65,674,000,000 | — | — |
| Dec 2022 | 46,385,000,000 | -31,661,000,000 | 6,994,000,000 | 96,820,000,000 | 65,702,000,000 | — | — |
| Dec 2021 | 42,518,000,000 | -46,958,000,000 | -9,015,000,000 | 109,314,000,000 | 73,308,000,000 | — | — |
| Dec 2020 | 26,145,000,000 | -17,031,000,000 | 3,439,000,000 | 118,481,000,000 | 80,599,000,000 | — | — |
| Dec 2019 | 5,920,000,000 | — | 1,710,000,000 | 129,944,000,000 | 78,246,000,000 | — | — |
| Dec 2018 | 5,193,000,000 | — | 1,486,000,000 | 34,986,000,000 | 20,859,000,000 | — | — |
| Dec 2017 | 4,929,000,000 | — | 1,574,000,000 | 33,551,000,000 | 21,704,000,000 | — | — |
| Dec 2016 | 4,391,000,000 | — | 1,195,000,000 | 33,707,000,000 | 17,360,000,000 | — | — |
| Dec 2015 | 4,041,000,000 | — | 1,186,000,000 | 31,748,000,000 | 17,324,000,000 | — | — |
TTM Snapshot
Revenues TTM
$45,700,000,000
NetIncome TTM
$6,291,000,000
OpCashFlow TTM
$0
Assets (Latest)
$92,603,000,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.11T | $1246.93 | — |
| JNJ | JOHNSON & JOHNSON | $658.00B | $273.04 | — |
| ABBV | AbbVie Inc. | $467.44B | $264.52 | — |
| MRK | Merck & Co., Inc. | $371.70B | $150.66 | — |
| NVSEF | NOVARTIS AG | $310.96B | $163.60 | — |
News headlines (Yahoo Finance, 1h cache)
Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.
2026-07-20 22:12 · Yahoo
Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today
2026-07-16 21:45 · Yahoo
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
2026-07-15 16:10 · Yahoo
Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
2026-07-14 12:00 · Yahoo
BMY Stock: Analysts See 16% Upside and a Strong Buy
2026-04-20 14:50 · Yahoo
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
2026-04-20 12:00 · Yahoo
Bristol-Myers Squibb Collaboration Adds New Dimension To Oncology Valuation Story
2026-04-19 01:11 · Yahoo
Can Myqorzo Drive Growth for Cytokinetics Amid Competition?
2026-04-17 17:37 · Yahoo
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
2026-04-15 18:59 · Yahoo
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings
2026-04-15 13:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.